| ATLANTIS - Attractor Landscape Analysis Toolbox for Cell Fate Discovery and Reprogramming |
Scientific Reports |
Shah O.S., Chaudhary M.F.A., Awan H.A., Fatima F., Arshad Z., Amina B., Ahmed M., Hameed H., Furqan M., Khalid S., Faisal A., Chaudhary S.U. |
2018 |
| Identification and characterization of SSE15206, a microtubule depolymerizing agent that overcomes multidrug resistance |
Scientific Reports |
Manzoor S., Bilal A., Khan S., Ullah R., Iftikhar S., Emwas A.-H., Alazmi M., Gao X., Jawaid A., Saleem R.S.Z., Faisal A. |
2018 |
| Aurora B prevents premature removal of spindle assembly checkpoint proteins from the kinetochore: A key role for Aurora B in mitosis |
Oncotarget |
Gurden M.D., Anderhub S.J., Faisal A., Linardopoulos S. |
2018 |
| Nicotine exposure augments renal toxicity of 5-azacytidine through p66shc: Prevention by resveratrol |
Anticancer Research |
Arany I., Hall S., Faisal A., Dixit M. |
2017 |
| Characterisation of CCT271850, a selective, oral and potent MPS1 inhibitor, used to directly measure in vivo MPS1 inhibition vs therapeutic efficacy |
British Journal of Cancer |
Faisal A., Mak G.W.Y., Gurden M.D., Xavier C.P.R., Anderhub S.J., Innocenti P., Westwood I.M., Naud S., Hayes A., Box G., Valenti M.R., De Haven Brandon A.K., O'Fee L., Schmitt J., Woodward H.L., Burke R., Vanmontfort R.L.M., Blagg J., Raynaud F.I., Eccles S.A., Hoelder S., Linardopoulos S. |
2017 |
| Natural products from Cuscuta reflexa Roxb. with antiproliferation activities in HCT116 colorectal cell lines |
Natural Product Research |
Riaz M., Bilal A., Ali M.S., Fatima I., Faisal A., Sherkheli M.A., Asghar A. |
2017 |
| Synthesis and evaluation of modified chalcone based p53 stabilizing agents |
Bioorganic and Medicinal Chemistry Letters |
Iftikhar S., Khan S., Bilal A., Manzoor S., Abdullah M., Emwas A.-H., Sioud S., Gao X., Chotana G.A., Faisal A., Saleem R.S.Z. |
2017 |
| Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle Kinase 1 (MPS1) Using a Structure-Based Hybridization Approach |
Journal of Medicinal Chemistry |
Innocenti P., Woodward H.L., Solanki S., Naud S., Westwood I.M., Cronin N., Hayes A., Roberts J., Henley A.T., Baker R., Faisal A., Mak G.W.-Y., Box G., Valenti M., De Haven Brandon A., O'Fee L., Saville H., Schmitt J., Matijssen B., Burke R., Van Montfort R.L.M., Raynaud F.I., Eccles S.A., Linardopoulos S., Blagg J., Hoelder S. |
2016 |
| 7-(Pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine-based derivatives for kinase inhibition: Co-crystallisation studies with Aurora-A reveal distinct differences in the orientation of the pyrazole N1-substituent |
Bioorganic and Medicinal Chemistry Letters |
Bavetsias V., Perez-Fuertes Y., McIntyre P.J., Atrash B., Kosmopoulou M., O'Fee L., Burke R., Sun C., Faisal A., Bush K., Avery S., Henley A., Raynaud F.I., Linardopoulos S., Bayliss R., Blagg J. |
2015 |
| Naturally occurring mutations in the MPS1 gene predispose cells to kinase inhibitor drug resistance |
Cancer Research |
Gurden M.D., Westwood I.M., Faisal A., Naud S., Cheung K.-M.J., McAndrew C., Wood A., Schmitt J., Boxall K., Mak G., Workman P., Burke R., Hoelder S., Blagg J., Van Montfort R.L.M., Linardopoulos S. |
2015 |
| Targeting the PPM1D phenotype; 2,4-bisarylthiazoles cause highly selective apoptosis in PPM1D amplified cell-lines |
Bioorganic and Medicinal Chemistry Letters |
Cheeseman M.D., Faisal A., Rayter S., Barbeau O.R., Kalusa A., Westlake M., Burke R., Swan M., Van Montfort R., Linardopoulos S., Jones K. |
2014 |
| Structure-based design of orally bioavailable 1 h -Pyrrolo[3,2- C ]pyridine inhibitors of mitotic kinase monopolar spindle 1 (MPS1) |
Journal of Medicinal Chemistry |
Naud S., Westwood I.M., Faisal A., Sheldrake P., Bavetsias V., Atrash B., Cheung K.-M.J., Liu M., Hayes A., Schmitt J., Wood A., Choi V., Boxall K., Mak G., Gurden M., Valenti M., De Haven Brandon A., Henley A., Baker R., McAndrew C., Matijssen B., Burke R., Hoelder S., Eccles S.A., Raynaud F.I., Linardopoulos S., Van Montfort R.L.M., Blagg J. |
2013 |
| Aurora isoform selectivity: Design and synthesis of imidazo[4,5- B ]pyridine derivatives as highly selective inhibitors of aurora-A kinase in cells |
Journal of Medicinal Chemistry |
Bavetsias V., Faisal A., Crumpler S., Brown N., Kosmopoulou M., Joshi A., Atrash B., Perez-Fuertes Y., Schmitt J.A., Boxall K.J., Burke R., Sun C., Avery S., Bush K., Henley A., Raynaud F.I., Workman P., Bayliss R., Linardopoulos S., Blagg J. |
2013 |
| Optimization of imidazo[4,5- b ]pyridine-based kinase inhibitors: Identification of a dual FLT3/aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia |
Journal of Medicinal Chemistry |
Bavetsias V., Crumpler S., Sun C., Avery S., Atrash B., Faisal A., Moore A.S., Kosmopoulou M., Brown N., Sheldrake P.W., Bush K., Henley A., Box G., Valenti M., De Haven Brandon A., Raynaud F.I., Workman P., Eccles S.A., Bayliss R., Linardopoulos S., Blagg J. |
2012 |
| Selective FLT3 inhibition of FLT3-ITD+acute myeloid leukaemia resulting in secondary D835Y mutation: A model for emerging clinical resistance patterns |
Leukemia |
Moore A.S., Faisal A., De Castro D.G., Bavetsias V., Sun C., Atrash B., Valenti M., De Haven Brandon A., Avery S., Mair D., Mirabella F., Swansbury J., Pearson A.D.J., Workman P., Blagg J., Raynaud F.I., Eccles S.A., Linardopoulos S. |
2012 |
| The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in Vivo |
Molecular Cancer Therapeutics |
Faisal A., Vaughan L., Bavetsias V., Sun C., Atrash B., Avery S., Jamin Y., Robinson S.P., Workman P., Blagg J., Raynaud F.I., Eccles S.A., Chesler L., Linardopoulos S. |
2011 |
| Cisplatin induces apoptosis through the ERK-p66shc pathway in renal proximal tubule cells |
Cancer Letters |
Clark J.S., Faisal A., Baliga R., Nagamine Y., Arany I. |
2010 |
| Structure-based design of imidazo[1,2-a]pyrazine derivatives as selective inhibitors of Aurora-A kinase in cells |
Bioorganic and Medicinal Chemistry Letters |
Bouloc N., Large J.M., Kosmopoulou M., Sun C., Faisal A., Matteucci M., Reynisson J., Brown N., Atrash B., Blagg J., McDonald E., Linardopoulos S., Bayliss R., Bavetsias V. |
2010 |
| Imidazo[4,5-b]pyridine derivatives as inhibitors of aurora kinases: Lead optimization studies toward the identification of an orally bioavailable preclinical development candidate |
Journal of Medicinal Chemistry |
Bavetsias V., Large J.M., Sun C., Bouloc N., Kosmopoulou M., Matteucci M., Wilsher N.E., Martins V., Reynisson J., Atrash B., Faisal A., Urban F., Valenti M., De Haven Brandon A., Box G., Raynaud F.I., Workman P., Eccles S.A., Bayliss R., Blagg J., Linardopoulos S., McDonald E. |
2010 |
| p66SHC-mediated mitochondrial dysfunction in renal proximal tubule cells during oxidative injury |
American Journal of Physiology - Renal Physiology |
Arany I., Faisal A., Clark J.S., Vera T., Baliga R., Nagamine Y. |
2010 |
| A cancer-associated Aurora a mutant is mislocalized and misregulated due to loss of interaction with TPX2 |
Journal of Biological Chemistry |
Bibby R.A., Tang C., Faisal A., Drosopoulos K., Lubbe S., Houlston R., Bayliss R., Linardopoulos S. |
2009 |
| The regulated assembly of a PKCe complex controls the completion of cytokinesis |
Nature Cell Biology |
Saurin A.T., Durgan J., Cameron A.J., Faisal A., Marber M.S., Parker P.J. |
2008 |
| The scaffold MyD88 acts to couple protein kinase C?? to toll-like receptors |
Journal of Biological Chemistry |
Faisal A., Saurin A., Gregory B., Foxwell B., Parker P.J. |
2008 |
| p66shc inhibits pro-survival epidermal growth factor receptor/ERK signaling during severe oxidative stress in mouse renal proximal tubule cells |
Journal of Biological Chemistry |
Arany I., Faisal A., Nagamine Y., Safirstein R.L. |
2008 |
| Protein kinases, from B to C |
Biochemical Society Transactions |
Cameron A.J., De Rycker M., Calleja V., Alcor D., Kjaer S., Kostelecky B., Saurin A., Faisal A., Laguerre M., Hemmings B.A., McDonald N., Larijani B., Parker P.J. |
2007 |
